Immunoglobulin News and Research

RSS

Will mRNA vaccine boosters be required for SARS-CoV-2 variants?

A new study shows that the highly effective mRNA Moderna vaccine designed against the original SARS-CoV-2 strain may lose some efficacy as new variants arise.

30 Aug 2021

Two mRNA vaccines are effective even without post-shot symptoms or prior SARS-CoV-2 infection

Vaccination with the two messenger RNA (mRNA) vaccines for SARS-CoV-2, the virus that causes COVID-19, yields a robust antibody response, even if a person did not develop significant symptoms following vaccination or did not have a prior SARS-CoV-2 infection.

26 Aug 2021

Analysis of antibody titer decay following vaccination or SARS-CoV-2 infection

A new study focused on the decrease in antibody titers following two doses of BNT162b2 vaccine or SARS-CoV-2 natural infection in Israel.

25 Aug 2021

Persistence of Anti-PF4 levels in VITT patients four months after AstraZeneca COVID-19 vaccine

A study published on medRxiv* preprint server reported the over-time changes in the ability of the serum to activate platelets in vitro.

25 Aug 2021

Study shows difference in antibody levels in response to SARS-CoV-2 infection and type of vaccination

In a recent study, researchers aimed to monitor the levels of the anti-SARS-CoV-2 spike IgG levels in populations that were subjected to routine tests.

24 Aug 2021

Expansion of seasonal betacoronavirus antibodies post-vaccination is associated with reduction in neutralization of the SARS-CoV-2 variants of concern

A new study determined the antibody response to SARS-CoV-2 and seasonal viruses induced by BNT162b2-Comirnaty vaccination in healthcare workers.

23 Aug 2021

New study reveals unique immune responses to SARS-CoV-2, Ebola and respiratory syncytial virus using B cell repertoire analysis

A new study has been published on the bioRxiv* preprint server, which takes a long-read repertoire amplification approach to better understand, compare and contrast B cell responses to emerging or endemic viruses.

23 Aug 2021

A combination of oral bacteria and intranasal vaccine provide protection from influenza A virus and COVID-19

A new study published in the journal mBio focuses on the role of nasal bacteria in eliciting virus-specific adaptive immunity.

20 Aug 2021

Study: PirB inhibits the self-renewal and differentiation capacities of neural stem cells

Aging-US published "PirB functions as an intrinsic suppressor in hippocampal neural stem cells" which reported that neural stem cells play pivotal roles during prenatal development and throughout life.

20 Aug 2021

SARS-CoV-2 antibodies found to neutralize bat coronavirus (RaTG13) in new study

A striking new study examines how far antibodies elicited by vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or by natural infection, can neutralize the closely related bat coronavirus (CoV) RaTG13.

19 Aug 2021

Durable highly protective T cell response to AAV-spike vaccine against COVID-19 pneumonia in mice

New research, available as a preprint on the bioRxiv* server, has focused on the role played by T cell immunity, particularly CD8+ cytotoxic T cells, on preventing lethal infection with SARS-CoV-2 in mice infused with peptide-loaded antigen-presenting dendritic cells (DCs).

19 Aug 2021

Data reinforces SAB-185’s potential to neutralize SARS-CoV-2 variants

A study, available on the pre-print server bioRxiv*, evaluated the neutralizing capacity of a fully human polyclonal antibody (SAB-185) against the Delta, Kappa, and Lambda variants using a lentiviral-based pseudovirus assay.

17 Aug 2021

Obtained SARS-CoV-2 immunity, naturally or via vaccination persists 12 months

In a research paper recently uploaded to the preprint server medRxiv* by Havervall et al. (August 12th, 2021), neutralizing antibody titers towards wild-type SARS-CoV-2 and several variants of concern in individuals having either been vaccinated or infected with mild COVID-19 one year earlier are assessed, finding a reduced neutralization capacity against some strains.

16 Aug 2021

Response to a third SARS-CoV-2 vaccine dose amongst immunocompromised

In a research paper recently uploaded to the preprint server medRxiv* by Schrezenmeier et al. (August 12th, 2021) the potential benefit of three vaccine doses in either a homogenous or heterogeneous dosing regimen amongst kidney transplant patients is assessed, finding that the search for viable vaccination approaches amongst these patients remains an urgent medical need.

16 Aug 2021

Certain intestinal bacteria induce cross-reactive IgA responses to the SARS-CoV-2 spike RBD

A new study finds that human gut bacteria can induce antibodies of the immunoglobulin A (IgA) subtype that cross-react with the SARS-CoV-2 spike RBD.

15 Aug 2021

Immunogenicity of mRNA vaccine against emerging strains of SARS-CoV-2 in immunocompromised patients

A study measured neutralization of SARS-CoV-2 and vaccine responses in immunocompromised patients with systemic inflammatory diseases.

11 Aug 2021

Plant-based virus-like particle vaccine induces durable immune response against SARS-CoV-2 variants

Scientists from Germany and Belgium have recently described the immunogenicity of a plant-based virus-like particle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine induces robust antibody and T cell responses for at least 6 months. Moreover, the vaccine demonstrates potent neutralizing efficacy against the B.1.1.7, B.1.351, and P1 variants of SARS-CoV-2.